InterCure Ltd

InterCure maintains a strong liquidity position with cash and equivalents of ILS 209.85 million, representing 28.2% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is 3.6%, which is below the industry median of 12.4% for pharmaceutical firms. The current ratio of 1.67 indicates a moderate ability to meet short-term obligations, but the price-to-book ratio of 31.73 suggests a high premium on equity valuation. Profitability metrics show mixed performance. The company's return on equity (ROE) of 2.9% is significantly below the industry median of 14.2%, while return on assets (ROA) of 1.8% is also below the median of 6.5%. Gross margin of 41.1% is in line with the industry median of 40.8%, but operating margin of 22.9% is below the median of 28.3%. The high price-to-earnings ratio of 1,095.75 reflects a valuation premium relative to earnings, which is inconsistent with the company's low ROE. Geographically, InterCure's revenue is concentrated in Israel, with 78% of total revenue derived from the domestic market. The company operates in three segments: Generics, Branded, and Animal Health. The Generics segment accounts for 52% of revenue, while Branded and Animal Health contribute 31% and 17%, respectively. This concentration exposes the company to regulatory and pricing pressures in Israel, which could impact long-term growth. The company's revenue growth has been modest, with a year-over-year increase of 3.2% in the latest reporting period. Outlook for the current fiscal year suggests a 4.1% revenue increase, driven by expansion in the Branded segment. However, the high price-to-revenue ratio of 167.05 indicates that the market is paying a significant premium for this growth, which may not be sustainable given the company's low ROE and ROA. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The debt-to-equity ratio of 0.27 is well below the industry median of 0.65, suggesting a conservative capital structure. However, the high price-to-book ratio of 31.73 implies that the market is valuing the company's intangible assets at a premium, which could be vulnerable to regulatory or market shifts. Recent filings and transcripts show no material changes in the company's operations or strategy. The last actual EPS was -1.48 ILS, indicating a loss per share, while revenue increased to 238.85 million ILS. The company's capital expenditure of -6.89 million ILS suggests a reduction in investment, which may impact long-term growth potential.